128 related articles for article (PubMed ID: 19863334)
1. Interferon: does it still have a role in the 21st century?
McLaughlin P; Sacchi S
Leuk Lymphoma; 2009 Oct; 50(10):1562-3. PubMed ID: 19863334
[No Abstract] [Full Text] [Related]
2. Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
Smith SM; Johnson J; Cheson BD; Canellos G; Petroni G; Oken M; Duggan D; Hurd D; Gockerman JP; Parker B; Prchal J; Peterson BA; ;
Leuk Lymphoma; 2009 Oct; 50(10):1606-17. PubMed ID: 19626540
[TBL] [Abstract][Full Text] [Related]
3. Rituximab maintenance therapy in follicular lymphoma.
Forstpointner R; Dreyling M
Curr Hematol Malig Rep; 2007 Oct; 2(4):213-8. PubMed ID: 20425372
[TBL] [Abstract][Full Text] [Related]
4. Hematology: Follicular lymphoma: maintenance therapy is (often) indicated.
Seymour JF
Nat Rev Clin Oncol; 2009 Nov; 6(11):624-6. PubMed ID: 19861993
[No Abstract] [Full Text] [Related]
5. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.
Salles G; Mounier N; de Guibert S; Morschhauser F; Doyen C; Rossi JF; Haioun C; Brice P; Mahé B; Bouabdallah R; Audhuy B; Ferme C; Dartigeas C; Feugier P; Sebban C; Xerri L; Foussard C
Blood; 2008 Dec; 112(13):4824-31. PubMed ID: 18799723
[TBL] [Abstract][Full Text] [Related]
6. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.
Ferreri AJ; Dognini GP; Verona C; Patriarca C; Doglioni C; Ponzoni M
Haematologica; 2007 Jan; 92(1):e1-2. PubMed ID: 17405748
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
8. Chlorambucil - rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: a clinical and biological analysis.
Laszlo D; Rabascio C; Andreola G; Pruneri G; Raia V; Calabrese L; Radice D; Saronni L; Martinelli G
Leuk Lymphoma; 2007 Feb; 48(2):437-8. PubMed ID: 17325914
[No Abstract] [Full Text] [Related]
9. Hematology: The case against rituximab maintenance.
Cheson BD
Nat Rev Clin Oncol; 2009 Nov; 6(11):622-4. PubMed ID: 19861992
[No Abstract] [Full Text] [Related]
10. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L
Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384
[No Abstract] [Full Text] [Related]
11. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
[TBL] [Abstract][Full Text] [Related]
12. [Advances in management of follicular lymphoma].
Zinzani PL
Rinsho Ketsueki; 2014 Oct; 55(10):1937-40. PubMed ID: 25297758
[No Abstract] [Full Text] [Related]
13. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?
Portlock CS; O'Connor OA; Straus DJ; Rosenzweig L; Dumitrescu O; Lin O; Maslak P
Leuk Lymphoma; 2006 Jul; 47(7):1260-4. PubMed ID: 16923555
[TBL] [Abstract][Full Text] [Related]
14. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
[No Abstract] [Full Text] [Related]
15. Increasing treatment options in indolent non-Hodgkin's lymphoma.
Solal-Céligny P
Semin Oncol; 2002 Apr; 29(2 Suppl 6):2-6. PubMed ID: 12040527
[TBL] [Abstract][Full Text] [Related]
16. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected].
Kimby E
Semin Oncol; 2002 Apr; 29(2 Suppl 6):7-10. PubMed ID: 12040528
[TBL] [Abstract][Full Text] [Related]
17. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
Jäeger G; Neumeister P; Brezinschek R; Höfler G; Quehenberger F; Linkesch W; Sill H
Eur J Haematol; 2002 Jul; 69(1):21-6. PubMed ID: 12270058
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy.
Al-Salman J; Salib H; Boonswang P
Med Oncol; 2001; 18(4):277-83. PubMed ID: 11918454
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
[TBL] [Abstract][Full Text] [Related]
20. 6th European Hematology Association Meeting. Frankfurt, Germany. June 21-24, 2001.
Maung K; D'Orazio AI
Clin Lymphoma; 2001 Sep; 2(2):74-9. PubMed ID: 11712544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
